0.00Open0.00Pre Close0 Volume0 Open Interest11.00Strike Price0.00Turnover1059.49%IV-45.31%PremiumDec 13, 2024Expiry Date3.43Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5628Delta0.0722Gamma1.63Leverage Ratio-0.7347Theta-0.0004Rho-0.92Eff Leverage0.0020Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet